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Introduction
The human epidermal growth factor receptor 2 (HER2 or
ErbB2) is over-expressed in several cancers, in particular in about
30% of breast tumors [1] and is indicative of a poor prognosis for
these patients. Members of the HER/EGFR family are cell-
surface receptors that have an intracellular tyrosine kinase domain
and an ectodomain consisting of four distinct domains including
the ligand-binding regions (domains 1 and 3) and two cysteine-rich
domains (domains 2 and 4). HER2 plays a fundamental role in
normal growth and development, eliciting a complex program of
intracellular signaling and cellular responses, initiated by hetero-
dimerization with other members of the HER family, in particular
HER3 and HER4 [2], that become dimerization competent
through ligand binding. Over-expression of HER2, usually the
result of gene amplification, allows the constitutive dimerization of
the receptor with HER3 devoid of ligand [3] and all liganded
members of the EGFR family, and is thus a major factor in the
development and maintenance of malignancy. Hence, HER2 is an
important target for cancer therapeutic and diagnostic develop-
ment. Of the HER2 binding monoclonal antibodies that are used
in the clinic, trastuzumab (HerceptinTM) binds to domain 4 [4]
while pertuzumab (PerjetaTM) binds to domain 2 [5].
Designed ankyrin repeat proteins (DARPins) [6,7,8] are a novel
class of small, highly stable binding proteins that can be selected by
ribosome display to bind target proteins with high affinity and can
be expressed in bacteria in high yields. Because of their small size,
DARPins targeting cell-surface proteins are expected to have
much better tissue penetration and higher clearance than
antibodies recognizing the same protein target when administered
in vivo. The DARPin H10-2-G3 (hereafter referred to as ‘G3’) has
been selected to bind HER2 with picomolar affinity [9]. This
DARPin has been found to be as reliable and even more specific
when compared to an FDA-approved anti-HER2 antibody used
for testing the status of HER2 in paraffin-embedded breast cancer
tissue [10]. G3 consists of only two ankyrin repeat motifs flanked
by N-terminal and C-terminal capping regions. Each of the 33-
residue ankyrin repeat motifs contain two antiparallel a-helices.
G3 has been randomized at six positions in each of the repeats and
contains four further mutations in the framework region. G3,
while binding to domain 4 of HER2 [10], does not compete with
trastuzumab in binding to HER2 (C. Jost and A. Plu¨ckthun,
unpublished data). Tumor targeting experiments with mice
bearing HER2-overexpressing human breast cancer xenografts
have shown high tumor accumulation correlating with the affinity
of the DARPins to HER2 [11].
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Knowledge of the three-dimensional structure of the G3-HER2
complex would be very valuable in understanding the structural
basis of the interaction between the DARPin and HER2 and
would facilitate protein engineering approaches for anti-HER2
DARPins that contain G3. In the current paper, we use
macromolecular computational docking methodology in combi-
nation with a number of different energetic and structural metrics
to construct a 3-dimensional atomic structural model of the
complex between G3 and HER2. We then selected putative
interacting amino acid residues on HER2 to mutagenize. By
analyzing the impact of these mutations on the interaction of G3,
we provide evidence that validates the structural model of the G3-
HER2 complex. Structural comparison with a subsequently solved
X-ray crystal structure (PDB id: 4HRN) of the complex provides
a quantitative measure of the accuracy of the computational
model.
Results and Discussion
Modeling the Structure of the G3-HER2 Complex
The construction of the three-dimensional structure of the
complex between HER2 and G3 commenced with the X-ray
crystal structure of HER2 in complex with trastuzumab [4] and
the X-ray crystal structure of the HER2-specific DARPin G3 [9].
G3 is one of the KEYL sequence family DARPins evolved by
affinity maturation and exhibits affinity of 90 pM to HER2. As
Cho et al. [4] describe in their crystal structure of the complex
between trastuzumab-Fab and the HER2 ectodomain, trastuzu-
mab binds to the domain 4 of HER2. While G3 also binds to
domain 4 of HER2, it does not compete with trastuzumab in
binding to the receptor (C. Jost and A. Plu¨ckthun, unpublished).
For this reason we used only domain 4 (residues #508–607) in
macromolecular docking to construct the structural model of the
G3-HER2 complex. This also has the effect of making the
computational task more tractable and facilitates the generation of
more accurate results through the use of a finer grid mesh for the
docking than otherwise would have been possible. Chain A
(residues #12–135) of the G3 structure was used in the modeling.
Prior to the macromolecular docking, the structure of the loop
containing residues #581–590 of domain 4 of HER2 was
modeled, since atomic coordinates of this region are missing in
the crystal structure of Cho et al. Prior experience in loop
modeling, both in our laboratory as well as elsewhere, has shown
that ab initio modeling of loops of 10 residues in length may be
done with reasonable reliability [12].
We performed rigid body macromolecular docking with these
two structures using ZDOCK [13] as described in Methods. This
suite of algorithms has performed quite well in the periodically
held Critical Assessment of Prediction of Interactions (CAPRI)
experiments [14]. Although we performed some limited energy
minimization of the final structural model, this approach to
modeling the complex excludes the possibility that significant
conformational changes (with respect to the apo structures) may
occur in either the HER2 or the G3 structure or both. Exclusion of
such changes is a safe assumption to make for the following
reasons: neither the X-ray crystal structure of trastuzumab bound
to HER2 nor that of the bispecific antibody bH1 bound to HER2
[15] showed any significant conformational changes in domain 4
of HER2 due to the complexation. Furthermore, an analysis [16]
of a number of X-ray crystal structures of DARPins bound to
different proteins did not show any significant conformational
changes in the DARPin structure. The grid size that we used in the
docking translates to a grid spacing of 1.2 A˚, which is a sufficiently
fine resolution for the docking, and at the same time implicitly
allows for some conformational ‘flexibility’ during the docking.
Numerous protein-protein docking studies over the past few
years, including the CAPRI experiments, have shown that more
accurate results are produced by using existing structural bi-
ological and biochemical experimental information to guide and
filter the computational results [17]. Experimentally determined
structures of complexes of DARPins with other proteins show that
the concave face of the DARPin structure is used in binding the
target [16]. This is consistent with expectations from the design [6]
as this face is randomized and amino acids mediating tight binding
are selected by ribosome display or phage display [7,18]. In
DARPins, the "constant" convex face, distal to the randomized
and selected concave face, is characterized by the presence of
a number of acidic amino acid residues, i.e. Glu 61, Glu 64, Glu
97, Asp 127, and Glu 130. Hence, in our computational docking,
we required that none of these acidic residues would be present in
the interacting surface of the ZDOCK docking solutions, i.e. such
docked solutions were ‘blocked out’. The top 2000 docked
solutions produced by this protocol were then scored and re-
ranked by the secondary scoring function ZRANK [19]. The top
ranked 20 solutions from this scoring step were selected for further
analysis. This analysis consisted of diverse computational metrics
as well as visual examination.
During the formation of a complex between two proteins, it can
be reasonably expected that favorable interactions between the
two molecules would be maximized, i.e. the thermodynamically
most stable complex would be that with the optimum interaction
energy. In protein-protein interactions this is largely achieved by
maximizing the shape complementarity, and hence maximizing
favorable van der Waals interactions between the two proteins.
For this reason, we chose the total interaction energy (IE) and
shape complementarity (Sc) between the two proteins as the
primary metrics to select the ‘best’ solution from the top 20
ZRANKed solutions. The empirical force field FoldX [20] was
used to evaluate IE. The FoldX force field contains parameters
derived from experimental data, and had been developed for the
purpose of evaluating the effects of mutations on protein and
protein-protein complex stability in a rapid and accurate manner.
We used the metric developed by Lawrence and Colman [21] to
measure Sc at the interface of each of the top ranked solutions.
This metric is easy to compute and was found by the developers to
distinguish between different classes of protein-protein complexes.
Table 1 lists the computed IE and Sc values for each of the top
ranked 20 solutions.
On the basis of these metrics, we selected ZDOCK solution
#45 as the optimal solution since it had both the highest shape
complementarity (0.748) as well as the highest interaction energy
(219.37 kcal mol21) between the two protein components. While
solutions #1 and #136 also have Sc greater than 0.7, visualizing
these two solutions made it apparent that G3 in these instances
was binding to the far C-terminal region of HER2 domain 4, such
that their orientation made clashes with the cell membrane likely.
We also considered the possibility of solution #195, which had the
second highest interaction energy of 218.66 kcal mol21.
Two more metrics were considered in making the final decision:
One was RPScore [22], which uses an empirically derived (from
statistical analysis of non-homologous interfaces in the Protein
Data Bank) amino acid residue pair potential matrix and gives the
likelihood of the occurrence of the given residue pairs across the
interface. The other was EC, the electrostatic complementarity at
the interface [23] of the complex, computed by solving the linear
Poisson-Boltzmann equation at the interface surfaces. These
calculations gave a RPScore value of +2.40 and an EC (Pearson)
Structural Model for the DARPin-HER2 Complex
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value of +0.35 for the solution #45 while for solution #195 these
values were +1.80 and +0.29, respectively. These additional
metrics confirmed our selection of solution #45 as the preferred
solution of the structure of the complex. (We note here that using
EC as a metric for filtering docked solutions in general is
impracticable as this calculation is very compute-intensive in
nature). This structure was then further refined to the final model
(see Text S1 for the coordinates of this model in Protein Data
Bank format) by performing a limited amount of constrained
energy minimization as described in Methods.
Analysis of the Structural Model
The resultant three-dimensional atomic structure of the
complete (all four domains) HER2 ectodomain – G3 complex is
shown in Figure 1 in a molecular surface representation. (This was
obtained by superimposing our computational structural model
with the HER2 crystal structure of Cho et al. [4]). Figure 1 also
depicts the structure of trastuzumab bound to HER2 (as given by
the X-ray crystal structure of Cho et al. [4]) superimposed on the
structural model of the complex. While the HER2 epitopes for the
DARPin G3 and trastuzumab are adjacent and very close to each
other, they do not overlap, in agreement with the experimental
observation that trastuzumab and G3 binding to HER2 are not
competitive with each other. It can also be seen that G3 does not
make any contacts with HER2 domains 1–3 (in agreement with
experimental observations), despite the fact that the latter were not
considered at all by our modeling of the complex.
The interface between HER2 domain 4 and G3 buries 961.8 A˚2
of total surface area. Figure 2 depicts the interactions between
HER2 and G3 present at the interface in a LigPlot figure [24].
With the exception of a backbone hydrogen bond between Ala
535 of HER2 and Asn 123 of G3, all the interactions are of van
der Waals in nature. The largest number of interactions across the
interface are by the HER2 amino acid residues Phe 555 (with G3
amino acid residues Ile 79, Phe 81, Phe 112, and Ile 119), Val 552
(with G3 residues Phe 81, Leu 86, and Phe 89), Ser 551 (with G3
residues Asp 77, Ala 78, and Ile 79), Val 563 (with G3 residues Ile
79 and Phe 112), Gly 550 (with G3 residues Tyr 46 and Leu 48),
and Leu 525 (with G3 residues Tyr 52 and Ala 56). We note that
of the interacting residues depicted in Figure 2, a relatively large
number of residues on the part of G3, and a relatively small
number of residues on the part of HER2, are aromatic. This
characteristic of DARPin-antigen complexes has been commented
on previously [6,7,16], and especially exposed Tyr residues are
well-known for facilitating protein-protein interactions in anti-
bodies and other complexes [25]. Five of the G3 interacting
residues are from the first ankyrin repeat, six residues are from the
second repeat, and three residues are from the C-cap region while
none are from the N-cap region. The interacting G3 amino acid
residues Tyr 46, Leu 48, Ala 56, His 57, Ala 78, Ile 79, Phe 81,
and Phe 89 are all at randomized positions on the DARPin.
Validation of the Structural Model
To validate our structural model of the HER2-G3 complex we
mutated HER2 amino acid residues at the interface predicted by
the model structure to make important interactions and stabilize
the complex. We chose to mutate to alanine the HER2 amino acid
residues Leu 525, Ser 551, Val 552, and Phe 555. According to
our structural model each of these residues makes interactions with
several G3 amino acids at the interface which are primarily van
der Waals in nature. Hence mutating these residues to alanine
would be expected to have a detrimental effect on G3-binding.
These expectations were further supported by analyzing the
complex structural model with the DrugScorePPI [26] web server,
which predicted that the Leu 525RAla, Ser 551RAla, Val
552RAla, and Phe 555RAla mutations should decrease the
binding free energy by 0.87, 0.6, 1.92, and 0.77 kcal mol21,
respectively. DrugScorePPI is a knowledge-based scoring function
for computational alanine scanning, derived from experimental
structures of complexes and alanine scanning results. Finally, we
utilized PROSA [27] to estimate whether the proposed mutations
in the HER2 structure were stabilizing or destabilizing. PROSA is
most frequently used to assess the quality of structural models of
proteins. The computation using the knowledge-based potentials
in PROSA, derived from 1352 high-resolution X-ray structures of
proteins, concluded that the mutations Leu 525RAla and Phe
555RAla should be stabilizing to the HER2 protein structure
while the mutations Ser 551RAla and Val 552RAla would not
cause any significant changes to the stability. Since none of these
amino acid residues are part of the epitope for trastuzumab, we
anticipated that the introduction of alanine mutations at each
position should not affect trastuzumab binding to the mutant
HER2 isoforms.
Site-directed mutagenesis was used to introduce the selected
mutations into a mammalian expression vector encoding residues
1–623 of the mature extracellular domain of HER2 and
incorporating a C-terminal Flag tag. The introduction of the
mutations had no effect on the expression yield and secretion of
soluble HER2, established by western blotting using an anti-Flag
monoclonal antibody on immune blotted cell culture supernatants
derived from HEK-293 T cells transiently transfected with
Table 1. Top ZRANKed docking solutions and their




solution # Sc IE (kcal mol21)
1 1698 0.425 26.35
2 1 0.704 215.40
3 566 0.663 28.51
4 45a 0.748 219.37
5 431 0.668 23.61
6 20 0.673 214.29
7 1094 0.414 23.72
8 41 0.672 213.46
9 380 0.658 210.42
10 136 0.710 213.33
11 240 0.400 20.99
12 88 0.444 210.98
13 21 0.520 215.42
14 24 0.557 213.65
15 1235 0.492 28.29
16 268 0.386 23.19
17 6 0.610 215.75
18 195 0.550 218.66
19 491 0.365 26.15
20 8 0.529 212.72
aThis ZDOCK solution was selected as the optimal or preferred solution for the
structural model of the G3 - HER2 complex.
doi:10.1371/journal.pone.0059163.t001
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plasmid vectors encoding either wild-type or mutant HER2
isoforms (data not shown). Purified recombinant HER2 was
isolated from supernatants of scaled-up transiently transfected
cultures of HEK-293F cells by immunoaffinity chromatography.
Surface Plasmon Resonance
Surface Plasmon Resonance (SPR) was utilized for the kinetic
interaction analyses of the HER2 wild type and mutant constructs.
A concentration series of each HER2 mutant was injected over
chip surfaces coated with either DARPin G3 or trastuzumab.
Binding sensorgrams shown in Figure 3 and the corresponding
binding rate parameters and overall affinity estimates listed in
Table 2 clearly indicated that none of the introduced alanine
mutations affected the binding of HER2 to immobilized
trastuzumab. This provided further evidence that none of these
mutations compromised structural integrity of the HER2 protein.
DARPin G3 has been analyzed in SPR using both BIAcore [9]
and ProteOn instruments (Nagy-Davidescu and Plu¨ckthun, un-
published). In many repeated measurements KD values of 90–
100 pM were obtained under all conditions, and this is consistent
with measurements on cells as well [1]. For these previous SPR
measurements, HER2 was coupled to the sensor, since amine
coupling of the DARPin may interfere with the HER2 interaction
of this very small protein. Indeed, a 30-fold lower affinity was
observed here when amine-coupling the wild type DARPin G3
(Table 2). However, since only relative affinities of HER2 mutants
were needed, this can still be used for comparisons.
More importantly, when compared with HER2 wild-type,
estimated binding parameters for interactions of the HER2
mutants with DARPin G3 showed very clear differences. Thus,
the Val 552RAla mutation generated the most significant
difference of the four mutant constructs tested with the measured
affinity being more than 100-fold weaker. Similarly, Leu 525RAla
and Phe 555RAla were also shown to significantly affect the
binding to G3 DARPin resulting in an 80-fold and 63-fold
reduction in affinity, respectively. The Ser 551RAla mutation
proved to change the binding least, generating only a 4-fold
reduction in affinity. In all four cases the dissociation rate constant
(kd) was most significantly affected and corresponded with the
overall affinity. In contrast, the association rate constant (ka) was
Figure 1. Structural model of the DARPin G3 (cyan) in complex with the human epidermal growth factor receptor 2 HER2 (green). In
magenta the structure of trastuzumab Fab bound to HER2 is shown superimposed on the G3-HER2 complex.
doi:10.1371/journal.pone.0059163.g001
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little affected, and it typically falls in a narrow window for protein-
protein interactions [28] as it is mainly influenced by translational
and rotational diffusion, which was little affected by the mutations.
Structural Comparison with the X-ray Crystallographic
Structure
During the preparation of this manuscript the X-ray crystallo-
graphic structure of the complex between H10-2-G3 and
a construct of HER2 domain 4 was solved at a resolution of
2.65 A˚ (C. Jost et al., submitted). After obtaining the coordinates
of the crystal structure (PDB id: 4HRN), we compared the
structure with that of the computational model.
The X-ray crystal structure has two complex molecules in the
asymmetric unit with each consisting of the complex between the
DARPin H10-2-G3 (chain A with residues #13–133 and chain B
with residues #13–135) and HER2 (chain C with residues #509–
579, and chain D with residues #509–578). Thus we shall refer to
the 2 complexes in the crystal structure as ‘ADxray’ and ‘BCxray’.
Superimposing the backbone atoms of the G3 residues #13–133
and HER2 residues #509–578 of ADxray and BCxray on the
corresponding atoms of the computational model (hereafter
referred to as the ‘model’) gives a root mean square deviation
(rmsd) value of 1.14 A˚ between ADxray and model and a value of
0.84 A˚ between BCxray and model. In the more detailed
Figure 2. LigPlot diagram of all G3 (red) - HER2 (blue) residue interactions in the model.
doi:10.1371/journal.pone.0059163.g002
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comparisons discussed below we shall restrict ourselves to the
comparison between the model and BCxray. Figure 4 depicts the
model superimposed (as described above) on BCxray.
The CAPRI experiments [14] use a number of standard metrics
to assess the structural models that are submitted. These include
fnat (the fraction of native contacts present in the model), fnon-nat
(the fraction of non-native contacts), L-RMSD (the ligand rmsd
after the receptor, defined as the larger of the two proteins, is
superimposed), and I-RMSD (the rmsd for the interface residues).
The interface in BCxray (analyzed with PDBsum [29]) consists of
amino acid residues Tyr 46, Leu 48, Tyr 52, Ala 56, His 57, Asp
77, Ala 78, Ile 79, Phe 81, Phe 89, Ile 90, His 92, Phe 112, Gly
122, Asn 123, and Gly 124 of the DARPin, and residues Phe 512,
Glu 521, Leu 525, Gln 526, Tyr 532, Val 533, Asn 534, Ala 535,
Asp 549, Gly 550, Ser 551, Cys 554, Phe 555, and Val 563 of
HER2. In the complex BCxray, these interface residues contribute
to a total of 26 residue-residue contacts, out of which 24 are
present in the model. This gives a fnat value of 0.92 for the model.
The fnon-nat value for the model is 0.47. The I-RMSD value (i.e.
for the interface residues) is 0.92 A˚, while the L-RMSD value for
the model is 1.84 A˚. (We note here that in deriving the L-RMSD
value we followed the CAPRI convention and treated the HER2
chains as the ‘ligand’. If instead, we take HER2 as the ‘receptor’
the ‘L-RMSD’ value is 1.38 A˚.) The CAPRI assessment classifies
models with fnat $0.5 and (L_RMSD #1.0 or I_RMSD #1.0) as
‘highly accurate’ models. Accordingly, this model can be classed as
‘highly accurate’. This however, should also be tempered by
possible ‘false positive’ interactions indicated by the fnon-nat value,
likely caused by the energy minimization in the final refinement.
In summary, we have, in this work, constructed a three-
dimensional atomic model of the complex between HER2 and the
DARPin G3 using computational methodologies and metrics. It
utilized the apo crystal structures of HER2 and the DARPin as well
as information on the binding face of the DARPin. The model was
tested with HER2 mutants selected from the structurally
characterized interface of the complex, showing reduced binding
to G3. The work described here not only resulted in a structural
model of reasonably good accuracy for the interaction between
HER2 and G3, but also provided a validated examination of the
capabilities of the computational methodologies.
Materials and Methods
Modeling
Preparation of the starting structures. The starting
structures for the protein-protein docking were derived from the
X-ray crystal structure of HER2 (i.e. ErbB2) in complex with
trastuzumab [4] (PDB id 1N8Z), and the X-ray crystal structure of
the DARPin H10-2-G3 [9] (PDB id 2JAB), referred to as ‘G3’.
Chain A (residues # 12–135) of the G3 structure was used in the
modeling. Only domain 4 of HER2 was utilized in the docking
calculations. In this domain, the atomic coordinates of the residues
# 581–590 are missing due to disorder. Hence, prior to the
macromolecular docking, the structure of this loop was modeled
using Modeller v. 7.6 [30]. From the 20 loops constructed for this
region, model #12, the one with the lowest value of –logePDF
(where PDF is the molecular probability density function), was
selected as the optimal model.
Figure 3. SPR binding sensorgrams for the interaction of HER2 wild type and mutant proteins with immobilized DARPin G3 (left
panels) and trastuzumab (right panels). Injected analyte (HER2) protein construct: wild type (A and F), Leu 525RAla (B and G), Ser 551RAla (C
and H), Val 552RAla (D and I) and Phe 555RAla (E and J). Typically, injected HER 2 protein concentrations were diluted three-fold in running buffer
from 81 nM to 1 nM except in B, D and E where the concentration series were diluted from 729 nM down to 9 nM. Overlayed triplicate binding
responses are shown (black lines). Binding data were globally fit to a simple 1:1 interaction model (orange lines).
doi:10.1371/journal.pone.0059163.g003




23 (s21) KD (nM) fold difference in KD
wild-typea 3.2260.20 1.0760.01 3.360.2 1.0
Leu525-Ala 1.4960.03 39.364.2 265630 79.7
Ser551-Ala 2.8560.59 3.562.1 12.863.1 3.8
Val552-Ala 1.6960.16 64.063.7 380639 114.4




24 (s21) KD (nM) fold difference in KD
wild-type 1.1960.09 1.5660.03 1.3160.13 1.0
Leu525-Ala 1.0460.01 1.3260.05 1.2660.03 1.0
Ser551-Ala 1.0760.03 1.4760.01 1.3860.04 1.0
Val552-Ala 0.9660.02 1.2860.08 1.3360.06 1.0
Phe555-Ala 1.0660.01 1.4860.02 1.3960.03 1.1
Note 1: The values given are the average values for three separate measurements and the uncertainties represent one standard deviation.
aNote 2: About 30-fold higher affinities are obtained when avoiding random amine coupling of this very small DARPin [9,36], (Nagy-Davidescu and Plu¨ckthun,
unpublished).
doi:10.1371/journal.pone.0059163.t002
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Macromolecular docking. For the docking of these two
protein structures we used the macromolecular docking program
ZDOCK v. 3.0.1 [13]. ZDOCK is a grid-based rigid body
docking algorithm, which discretizes the two proteins (labeled the
‘‘receptor’’ and the ‘‘ligand’’) into grids, and performs global scans
of the rotational and translational space of the ligand with respect
to the receptor, with each relative orientation scored by a shape
complementarity function. In our docking, we designated domain
4 of HER2 as the ‘‘receptor’’ and the DARPin G3 as the ‘‘ligand’’.
Our grid size of 128 yielded a grid spacing of 1.2 A˚, while the
rotational sampling was done with an interval of 6 degrees. The
search space for ZDOCK was effectively reduced by requiring that
the docking solutions excluded the convex face of G3. This was
done by specifying that the amino acid residues Glu 61, Glu 64,
Glu 97, Asp 127, and Glu 130 that are on the convex face of G3
be absent from the interacting surface of the ZDOCK docking
solutions, i.e. these residues were ‘blocked out’ during the docking.
The top 2000 docked solutions produced by this protocol were
then scored and re-ranked by the secondary scoring function
ZRANK [19]. This function is a linear weighted sum of van der
Waals, Coulomb, and desolvation energy terms, where the optimal
weights had been obtained by training the function on a bench-
mark set of protein-protein complexes. The top ranked 20
solutions from this step were selected for further analysis.
We used the total interaction energy (IE) and shape comple-
mentarity (Sc) between the two proteins as the primary metrics to
select the ‘best’ solution from the top 20 ZRANKed solutions. The
empirical force field FoldX [20] was used to evaluate the
interaction IE. This force field free energy consists of a linear
combination of terms due to van der Waals energy, solvation,
hydrogen bonding, Coulomb electrostatics, and entropy changes.
We used the metric developed by Lawrence and Colman [21] to
measure the shape complementarity Sc at the interface of each of
the top ranked solutions.
We also used the computed metrics RPScore and EC in the
final choice of the optimal solution. RPScore [22] uses an
empirically derived (from statistical analysis of non-homologous
interfaces in the Protein Data Bank) amino acid residue pair
potential matrix and gives the likelihood of the occurrence of the
given residue pairs across the interface. EC, the electrostatic
complementarity at the interface [23] of the complex, was
computed by solving the linear Poisson-Boltzmann equation at
the interface surfaces.
Refinement and analysis of the model. Prior to the
structural characterization of the final optimal solution, the
selected top solution of the complex structure was further refined
by performing a limited amount of constrained energy minimiza-
tion with the program Discover v. 2.98 within InsightII v.2005
(Accelrys, Inc.). After adding hydrogen atoms to the structure, the
energy was first minimized with 500 steps of steepest descents,
holding the backbone of HER2 domain 4 fixed and tethering the
backbone of G3 with a force constant of 10.0 kcal A˚22. Next, 100
steps of steepest descents were performed by tethering the
backbone of HER2 domain 4 with a force constant of 5.0 kcal
A˚22. The CVFF force field was used with a distance-dependant
dielectric and no Morse or cross terms in the application of the
force field. The resultant structure of the complex was analyzed
and the interface between HER2 and G3 was characterized using
LigPlot [24].
Molecular and Cell Biology
The mammalian expression vector pME18s.HER2-623, encod-
ing the natural signal peptide and residues 1–623 of the
extracellular domain of HER2, and incorporating a C-terminal
Flag tag, was used as a template for site-directed mutagenesis.
Selected residues were mutated using the QuikChange site-
directed mutagenesis protocol (Stratagene) and the mutagenic
primer pairs listed in Table S1. The successful incorporation of
mutations was confirmed by DNA sequencing.
The culture and transient transfection of human 293 T
fibroblasts was performed as previously described [31]. The
successful biosynthesis and secretion of wild-type and mutant
HER2 isoforms was established by western blotting of culture
supernatants using an anti-Flag tag-specific monoclonal antibody.
For the purification of recombinant HER2 ectodomain, suspen-
sion-adapted cultures (200 ml) of Freestyle 293-F cells (Invitrogen)
grown in Freestyle 293 Expression Medium were transiently
transfected with plasmid DNA using polyethylenimine (PEI; [32]).
Following culture for 7–9 days, supernatants were harvested and
recombinant HER2 purified by anti-Flag immunoaffinity chro-
matography [33].
Surface Plasmon Resonance
All SPR experiments were performed at 25uC using Bio-Rad’s
ProteOn XPR36 array biosensor [34]. A standard amine-coupling
protocol was employed to immobilize G3 DARPin on a GLC chip
Figure 4. The computational model of the complex super-
imposed on the B and C chains of the X-ray crystal structure
(BCxray). The G3 chains of the model and BCxray are in yellow and
cyan, respectively, while the HER2 chains of the model and BCxray are
shown in red and green, respectively.
doi:10.1371/journal.pone.0059163.g004
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surface in 16 HBS-P buffer (10 mM HEPES, 150 mM NaCl,
0.05% (v/v) Tween 20) at a constant flow rate of 30 ml/min.
Briefly, with instrumental fluidics oriented in the ‘‘vertical’’
direction, a single lane on the chip surface was activated by a 5-
min injection of a freshly prepared mixture consisting of 2.5 mM
sulfo-NHS and 10 mM EDC. G3 DARPin solution (15 mg/ml in
10 mM sodium acetate, pH 5.0) was then injected for 5 min and
any residual reactive sites deactivated by a final 5-min injection of
1 M ethanolamine (pH 8.5). Approximately 1,200 RU (1 RU
= 1 pg of protein/mm2) of G3 DARPin was coupled using this
method. Trastuzumab was captured onto the SPR sensor chip
surface using a previously described Protein G’ capture method
[35]. Briefly, Protein G’ (Sigma-Aldrich) was coupled in a single
lane on a GLC chip at 2,200 RU using an identical amine
coupling method described for G3 DARPin except that Protein G’
was injected at 50 mg/ml in 10 mM sodium acetate, pH 4.0. A
single injection of trastuzumab at (5 mg/ml, 100 ml/min for
30 sec) in the vertical orientation resulted in a consistent capture of
approximately 1,300 RU of protein across entire Protein G’ lane.
No significant dissociation (drift) of trastuzumab from the Protein
G’ surface was observed (drift #1 RU/600 sec).
The ‘One-Shot Kinetics’ approach of Bravman et al. [34] was
utilized for binding analyses of HER2 proteins. Binding assays
were performed in 16 HBS-EBP+ buffer (10 mM HEPES,
150 mM NaCl, 3 mM EDTA, 0.1% [w/v] BSA; 0.05% [v/v]
Tween 20) with the instrumental fluidics oriented in ‘‘horizontal’’
direction. Six concentrations of HER2 (including ‘‘zero buffer
blank’’) were injected simultaneously over amine-coupled G3
DARPin or Protein G’-captured trastuzumab at 30 mL/min for
120 sec. The dissociation phase was monitored until all of the
bound HER2 protein had dissociated from the DARPin-coupled
surface. This was possible, since random amine coupling of the
DARPin lowered its known KD of 90–100 pM about 30-fold to
3 nM (Table 2), while the reverse set-up leads to almost no
dissociation. In case of the trastuzumab-HER2 complex, complete
dissociation was not achievable in a practicable timeframe.
Consequently, after each binding cycle, the Protein G’ surface
was regenerated in the vertical direction with a single injection of
10 mM glycine pH 1.5 (100 ml/min, 18 sec). Trastuzumab was
recaptured for any subsequent binding cycles.
All SPR binding data were processed using the Scrubber-Pro
software package (www.biologic.com.au). To determine the kinetic
rate constants (ka and kd) of the binding interactions, binding data
were fit globally to a 1:1 interaction model and the ratio of these
rate constants (kd/ka) yielded the value for the equilibrium
dissociation constant (KD).
Structural Analysis
Structural superimposition and comparison was done with
ProFit v. 2.5.3 (A.C.R. Martin, and C.T. Porter, www.bioinf.org.
ac.uk/software/profit/) while the interface analysis was performed
with PDBsum [29] (www.ebi.ac.uk/pdbsum). Figures 1 and 4 were
prepared with PyMol v. 1.5.0.4 (Schro¨dinger, LLC.).
Supporting Information
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